Plant Name: Rhamnus japonica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.346E-09 | 1.652E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 4.927E-07 | 4.664E-04 | FABP3, PPARA, PPARD, PPARG |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 1.008E-06 | 8.132E-04 | FABP3, FFAR1, PPARG, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 4.313E-06 | 2.295E-03 | FFAR4, PPARA, PPARD, PPARG |
| BP | GO:0008283; cell proliferation | GO:0048660; regulation of smooth muscle cell proliferation | 6.601E-06 | 3.125E-03 | HPGD, PPARD, PPARG, TERT |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 9.151E-06 | 3.986E-03 | PPARA, PPARG |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 9.152E-06 | 3.986E-03 | FABP3, PPARA, PPARG, TLR2 |
| BP | GO:0051179; localization | GO:0010887; negative regulation of cholesterol storage | 1.372E-05 | 5.332E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:0010871; negative regulation of receptor biosynthetic process | 1.372E-05 | 5.332E-03 | PPARA, PPARG |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.372E-05 | 5.332E-03 | ALOX15, HPGD |
| MF | GO:0005488; binding | GO:0050543; icosatetraenoic acid binding | 1.372E-05 | 5.332E-03 | FABP3, PPARG |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 1.445E-05 | 5.332E-03 | PPARA, PPARD, PPARG |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 2.533E-05 | 8.756E-03 | PPARA, PPARD, PPARG |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.074E-13 | 2.572E-11 | FABP2; FABP3; FABP4; FABP5; PPARG; PPARA; PPARD |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 3.419E-04 | 1.413E-02 | MAPK1; PPARG |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.360E-04 | 2.592E-02 | MAPK1; PPARA; TSHR |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.419E-04 | 1.413E-02 | ALOX15; CYP3A4 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.323E-03 | 2.734E-02 | MAPK1; PPARD |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.277E-03 | 2.734E-02 | FABP4; TSHR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.716E-03 | 3.040E-02 | ALDH1A1; CYP3A4 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 2.159E-03 | 3.346E-02 | MAPK1; TLR2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT; TLR2 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | FAAH |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PPARD; PPARD; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PPARG; PPARG |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| C00-D49: Neoplasms | Breast cancer | C50 | TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Melanoma | C43 | TERT; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TLR2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; PPARG |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | FAAH |
| C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; TLR2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | FAAH; CYP3A4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | FAAH |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; TLR2 |